Nektar Therapeutics(NASDAQ : NKTR)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Loading NKTR News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-3.48%||80.47||1.8%||$677.67m|
|ANAC||Anacor Pharmaceuticals, Inc.||-0.14%||99.06||15.2%||$320.35m|
|REGN||Regeneron Pharmaceuticals, Inc.||-4.95%||339.48||3.1%||$301.85m|
|ALXN||Alexion Pharmaceuticals, Inc.||-8.56%||112.99||2.5%||$274.13m|
|VRTX||Vertex Pharmaceuticals Incorporated||-7.14%||81.90||2.6%||$124.14m|
|BMRN||BioMarin Pharmaceutical Inc.||-7.94%||77.01||4.0%||$117.35m|
|SRPT||Sarepta Therapeutics, Inc.||3.58%||18.52||49.4%||$116.18m|
|CPXX||Celator Pharmaceuticals, Inc.||0.13%||30.19||8.5%||$107.30m|
|A||Agilent Technologies, Inc.||-5.48%||44.12||1.0%||$94.74m|
|IONS||Ionis Pharmaceuticals, Inc.||-6.91%||21.97||8.6%||$94.46m|
Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its products includes of drug candidates of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. The company provides small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. The company was founded in 1990 and is headquartered in San Francisco, CA.